What is APRE stock price today?

Visit our real-time dashboard for the current APRE stock price and live market data.

Is APRE stock going up or down today?

APRE stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy APRE stock now?

The decision to buy APRE depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is APRE a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for APRE based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is APRE stock overvalued or undervalued?

Use our DCF valuation calculator to determine if APRE is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is APRE's P/E ratio?

P/E ratio data for APRE will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is APRE's market cap?

APRE (Aprea Therapeutics Inc) has a market capitalization of $0.01 billion, making it a small-cap stock.

What is APRE's price to book ratio?

Price-to-book ratio for APRE is available on our dashboard along with other valuation metrics.

Does APRE pay dividends?

APRE does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is APRE's dividend yield?

APRE does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is APRE stock a good long-term investment?

APRE's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is APRE's revenue growth rate?

Revenue growth data for APRE is available on our dashboard with detailed financial statement analysis.

Profitability metrics for APRE are available on our dashboard with complete income statement analysis.

What are the risks of investing in APRE?

Key risks for APRE include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does APRE compare to its competitors?

Compare APRE to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize APRE's performance and positioning.

What is APRE's stock price target for 2026?

Visit our prediction page for AI-powered price targets for APRE with bull, base, and bear case scenarios.

What do analysts say about APRE?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for APRE. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is APRE's next earnings report?

APRE reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

APRE - Aprea Therapeutics Inc

NYSE * Healthcare * Biotechnology

$0.00

+$0.00 (+0.00%)

About Aprea Therapeutics Inc

Aprea Therapeutics Inc (APRE) common stock

Price Chart

Loading chart...

APRE Key Statistics

Market Cap

$10.40M

How APRE Compares to Peers

APRE is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 0

Growth Rank

N/A

of 0

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
APRE(This stock)	$10.40M	N/A	0%	0.0%	-
AMGNAmgen Inc	$188.67B	24.3	0%	0.0%	vs AMGN
GILDGilead Sciences	$160.15B	17.5	0%	0.0%	vs GILD
VRTXVertex Pharmaceuticals	$106.87B	29.7	0%	0.0%	vs VRTX
REGNRegeneron Pharmaceuticals	$59.10B	13.9	0%	0.0%	vs REGN
BIIBBiogen Inc	$29.33B	21.4	0%	0.0%	vs BIIB

Data Updated: July 20, 2026 at 2:08 PM EDT

Ready to invest in APRE?

Commission-free trading available. Affiliate links.

APRE Lician Score

5% confidence

4.0/10

Neutral

APRE has a Lician Score of 4/10 (Average). Areas of concern: Growth.

value

5.0

growth

2.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates APREacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

APRE Financial Snowflake

5-axis analysis across key investment dimensions

4.4/10

Neutral

5.0

Value

Valuation vs. sector peers

2.0

Growth

Revenue & earnings trajectory

5.0

Quality

Profitability & moat strength

5.0

Momentum

Price trends & analyst sentiment

5.0

Safety

Financial stability & risk

Upcoming Events for APRE

Dashboard

Enter a ticker to analyze